...A. Overview: With focus on strong execution, continued to serve patients, advance strategic priorities and delivered another strong financial qtr. 1. B. Alzheimer's Disease: Completed submission for US approval of aducanumab, unprecedented opportunity for patients and Co. to potentially bring to market the first therapy to reduce devastating clinical decline and meaningfully change the course of Alzheimer's disease. 1. Submission followed ongoing collaboration with FDA and include data from comprehensive clinical development program, including EMERGE, first positive Phase 3 study ever in this space, together with supporting data from Phase 3 ENGAGE study and positive results from Phase 1b PRIME study. a. 2. Co.'s data show that aducanumab may help to reduce decline of cognitive function and help patient's ability to perform certain activities of daily living, which for some patients may result in independence for longer period of time. 3. Anticipates receiving response from FDA within 60...
